<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537429</url>
  </required_header>
  <id_info>
    <org_study_id>18922A</org_study_id>
    <nct_id>NCT04537429</nct_id>
  </id_info>
  <brief_title>A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab</brief_title>
  <official_title>An Open-label, Single-dose, Pharmacokinetic Study to Evaluate IV Eptinezumab in Children and Adolescents With Migraine, Followed by an Optional, Multiple-dose, Open-label Extension Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate how the body absorbs, distributes, and get rid of&#xD;
      eptinezumab when given directly into a vein.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, open-label pharmacokinetic study with eptinezumab, consisting of a&#xD;
      single-dose, 20-week main study period (Part A) and an optional 44-week multiple-dose&#xD;
      extension period (Part B).&#xD;
&#xD;
      The main study period includes a single IV infusion of eptinezumab. The optional extension&#xD;
      period includes 3 additional eptinezumab infusions 12 weeks apart (reflecting recommended&#xD;
      dosing interval in adults), for a total of up to 4 infusions over the course of the study.&#xD;
&#xD;
      At least 32 patients with migraine will be enrolled: 16 patients aged 6 to 11 years, and 16&#xD;
      patients aged 12 to 17 years, inclusive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC) (0-infinity) eptinezumab</measure>
    <time_frame>From dosing to week 20</time_frame>
    <description>Area under the plasma concentration curve for eptinezumab from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax eptinezumab</measure>
    <time_frame>From dosing to week 20</time_frame>
    <description>Maximum observed plasma concentration of eptinezumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>From dosing to week 20</time_frame>
    <description>Plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz)</measure>
    <time_frame>From dosing to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of anti-eptinezumab antibodies (ADA)</measure>
    <time_frame>From screening to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of anti-eptinezumab antibodies for neutralizing activity (NAb)</measure>
    <time_frame>From screening to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Migraine in Children</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Eptinezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptinezumab</intervention_name>
    <description>up to four iv infusions of eptinezumab</description>
    <arm_group_label>Eptinezumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has a diagnosis of migraine with or without aura according to&#xD;
             international classification of headache disorders (ICHD)-3 (in the opinion of the&#xD;
             investigator) for ≥6 months prior to the Screening Visit and has a frequency of&#xD;
             migraine ≥4 migraine days per month for at least 3 months prior to the Screening&#xD;
             Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has been exposed to any monoclonal antibody treatment (including exposure&#xD;
             in a study) &lt;6 months prior to the Screening Visit.&#xD;
&#xD;
        Other in- and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NW FL Clinical Research Group LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Premiere Research Institute at Palm Beach Neurology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407-3234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>College Park Family Care Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Head Pain and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236-4604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Road Runner Research Ltd</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

